What’s next for the weight loss drug maker

Shares of Danish biotech Zealand Pharma recently plunged after detailed data on its weight loss drug survodutide showed far higher patient dropout rates than leading treatments, prompting analysts to slash peak sales forecasts and rethink the company’s obesity strategy. But while the market’s enthusiasm for the drug has meaningfully cooled, investors are shifting focus to…

Read More

Lilly, Novo, Pfizer look to new weight loss drugs

Drugmakers are only months into introducing GLP-1 pills and navigating huge changes in how patients pay for weight-loss drugs. Even so, they’re already outlining their visions for the future of obesity drugs. At the American Diabetes Association’s Scientific Sessions in New Orleans last week, drugmakers pitched doctors and investors on the idea of new shots…

Read More